Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AKRO

Akero Therapeutics Inc

Jan 29 • 03:02PM ET

54.38

Dollar change +2.91
Percentage change 5.65	%

Healthcare • Biotechnology • USA • NASD

Peers: MDGL ARWR HALO GNFT ALLK VKTX NBIX ENTA GALT SLDB

| Held by: IWM VTI XBI IWN VXF IBB SCHA SURI VTWO DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.75	Insider Own	16.44%	Shs Outstand	69.61M	Perf Week	117.34%
Market Cap	3.80B	Forward P/E	-	EPS next Y	-4.75	Insider Trans	-4.83%	Shs Float	58.32M	Perf Month	88.23%
Income	-237.22M	PEG	-	EPS next Q	-1.17	Inst Own	97.86%	Short Float	5.74%	Perf Quarter	85.40%
Sales	0.00M	P/S	-	EPS this Y	-39.67%	Inst Trans	3.58%	Short Ratio	3.21	Perf Half Y	101.25%
Book/sh	10.61	P/B	5.13	EPS next Y	-17.59%	ROA	-32.66%	Short Interest	3.35M	Perf Year	145.83%
Cash/sh	10.28	P/C	5.29	EPS next 5Y	-17.56%	ROE	-35.90%	52W Range	15.32 - 58.40	Perf YTD	95.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.03%	ROI	-30.65%	52W High	-6.89%	Beta	-0.10
Dividend TTM	-	Quick Ratio	17.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	254.95%	ATR (14)	3.98
Dividend Ex-Date	-	Current Ratio	17.25	EPS Y/Y TTM	-59.03%	Oper. Margin	-	RSI (14)	86.01	Volatility	10.23% 6.58%
Employees	56	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	67.36
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-46.82%	Payout	-	Rel Volume	3.00	Prev Close	51.47
Sales Surprise	-	EPS Surprise	-19.49%	Sales Q/Q	-	Earnings	Nov 08 BMO	Avg Volume	1.04M	Price	54.38
SMA20	83.15%	SMA50	81.39%	SMA200	105.79%	Trades		Volume	2,682,410	Change	5.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-25	Reiterated	H.C. Wainwright	Buy	$50 → $72
Nov-18-24	Initiated	Citigroup	Buy	$65
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

Today 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) +5.65%
Jan-28-25 09:30PM	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
11:14AM	Akeros cirrhosis treatment shows promise in Phase IIb study (Clinical Trials Arena)
08:40AM	Why Akero Therapeutics Inc. (AKRO) Surged on Monday (Insider Monkey)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +97.52%
04:01PM	Loading…
04:01PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:13PM	Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data (GuruFocus.com)
11:27AM	Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results (Investopedia)
11:10AM	Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal (GuruFocus.com)
10:57AM	Akero Therapeutics Stock Doubles on Liver Data (Barrons.com)
09:01AM	Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why (Benzinga)
06:30AM	Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study (GlobeNewswire)
Jan-24-25 04:05PM	Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jan-13-25 07:00AM	Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD (GlobeNewswire) -8.90%
Jan-09-25 12:18PM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
07:00AM	Loading…
Jan-07-25 07:00AM	Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-24 12:59PM	Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-26-24 07:00AM	Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-24 11:00AM	Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire) -5.61%
Nov-13-24 04:05PM	Akero Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-12-24 11:00PM	Akero Therapeutics Advances in MASH Treatment Trials (TipRanks)
Nov-08-24 07:00AM	Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:06AM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims of Misconduct on Your Behalf (Newsfile)
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-21-24 07:00AM	Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-17-24 03:02PM	State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares (GuruFocus.com)
Oct-16-24 08:44AM	Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin (Insider Monkey)
Oct-15-24 06:10PM	Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds (Insider Monkey)
Sep-30-24 07:00AM	Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
01:12AM	Loading…
Sep-12-24 01:12AM	Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc (GuruFocus.com)
Sep-09-24 07:00AM	Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH (GlobeNewswire)
Sep-05-24 12:02AM	Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 04:05PM	Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-24 02:53PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-16-24 12:00PM	Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-28-24 10:40AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-24-24 01:04PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-21-24 11:06AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) +6.52%
Jun-19-24 02:45PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-17-24 10:23AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-13-24 03:57PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-11-24 07:00AM	Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jun-10-24 10:14AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-08-24 08:15AM	Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 (GlobeNewswire)
Jun-06-24 10:39AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-03-24 09:57AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-30-24 09:16PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-29-24 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 02:12PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) -7.76%
May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.00%
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)
06:00AM	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study (GlobeNewswire)
04:00AM	Akero strengthens MASH drugs case with new study data (BioPharma Dive)
Mar-01-24 09:55AM	Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know (Zacks)
Feb-29-24 08:00AM	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-06-24 10:48AM	Cramer's Stop Trading: Akero Therapeutics (CNBC TV) -12.25%
Feb-05-24 09:55AM	Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-30-24 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.22%
Jan-03-24 08:15AM	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.41%
Dec-18-23 07:00AM	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program (GlobeNewswire)
Dec-13-23 03:06AM	Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ... (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
12:36PM	Hedge Fund and Insider Trading News: Jeff Ubben, Bill Ackman, Saba Capital Management, Akero Therapeutics Inc (AKRO), Verizon Communications Inc. (VZ) and More (Insider Monkey)
Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Jonathan	Chief Operating Officer	Jan 24 '25	Option Exercise	6.36	43,064	274,059	261,147	Jan 27 06:08 PM
Cheng Andrew	President and CEO	Jan 23 '25	Option Exercise	0.61	50,000	30,750	746,062	Jan 27 06:07 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	53,591	1,403,012		Jan 27 04:24 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	69,073	1,808,331		Jan 27 04:24 PM
PATRICK D LAMY	Officer	Jan 27 '25	Proposed Sale	26.18	6,000	157,080		Jan 27 04:23 PM
Andrew Cheng	President, CEO and Director	Jan 27 '25	Proposed Sale	57.03	120,000	6,843,600		Jan 27 04:19 PM
Timothy Rolph	Officer	Jan 27 '25	Proposed Sale	57.03	68,750	3,920,813		Jan 27 04:06 PM
Young Jonathan	Chief Operating Officer	Jan 02 '25	Sale	28.03	10,000	280,330	218,083	Jan 06 02:08 PM
Jonathan Young	Officer	Jan 02 '25	Proposed Sale	27.82	70,000	1,947,400		Jan 02 04:29 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 16 '24	Sale	29.13	1,000	29,130	34,258	Dec 18 09:03 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Option Exercise	21.10	9,074	191,461	104,722	Dec 18 09:01 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Sale	29.11	9,074	264,117	95,648	Dec 18 09:01 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Option Exercise	19.87	3,800	75,506	182,137	Dec 18 08:52 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Sale	31.10	3,800	118,172	178,337	Dec 18 08:52 PM
PATRICK D LAMY	Officer	Dec 16 '24	Proposed Sale	28.89	1,000	28,890		Dec 16 04:30 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Option Exercise	19.87	2,450	48,682	180,787	Dec 12 08:44 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Sale	30.91	4,818	148,934	178,337	Dec 12 08:44 PM
Young Jonathan	Chief Operating Officer	Dec 10 '24	Sale	30.79	2,503	77,067	203,783	Dec 12 08:38 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 10 '24	Sale	30.79	925	28,481	17,858	Dec 12 08:29 PM
Yale Catriona	Chief Development Officer	Dec 10 '24	Sale	30.79	2,810	86,520	71,348	Dec 12 08:28 PM
White William Richard	Chief Financial Officer	Dec 10 '24	Sale	30.79	2,817	86,735	38,335	Dec 12 08:26 PM
Cheng Andrew	President and CEO	Dec 10 '24	Sale	30.79	7,855	241,855	597,562	Dec 12 08:24 PM
Timothy Rolph	Officer	Dec 10 '24	Proposed Sale	30.79	25,000	769,750		Dec 10 04:25 PM
Cheng Andrew	President and CEO	Dec 02 '24	Option Exercise	21.10	25,000	527,500	630,417	Dec 04 07:36 PM
Cheng Andrew	President and CEO	Dec 02 '24	Sale	32.09	25,000	802,250	605,417	Dec 04 07:36 PM
Young Jonathan	Chief Operating Officer	Dec 02 '24	Sale	32.13	10,000	321,310	206,286	Dec 04 07:34 PM
Yale Catriona	Chief Development Officer	Nov 15 '24	Option Exercise	21.10	9,061	191,187	83,219	Nov 19 09:57 PM
Yale Catriona	Chief Development Officer	Nov 15 '24	Sale	27.73	9,061	251,274	74,158	Nov 19 09:57 PM
Yale Catriona	Chief Development Officer	Nov 06 '24	Option Exercise	0.61	10,000	6,150	84,158	Nov 08 05:06 PM
Yale Catriona	Chief Development Officer	Nov 06 '24	Sale	35.19	10,000	351,890	74,158	Nov 08 05:06 PM
CATRIONA YALE	Officer	Nov 06 '24	Proposed Sale	32.74	10,000	327,400		Nov 06 05:01 PM
Young Jonathan	Chief Operating Officer	Nov 01 '24	Option Exercise	21.09	40,716	858,700	267,002	Nov 05 09:04 AM
Young Jonathan	Chief Operating Officer	Nov 01 '24	Sale	31.57	50,716	1,601,252	216,286	Nov 05 09:04 AM
Cheng Andrew	President and CEO	Nov 01 '24	Option Exercise	21.10	108,366	2,286,523	686,697	Nov 05 09:00 AM
Cheng Andrew	President and CEO	Nov 01 '24	Sale	31.73	108,366	3,438,312	605,417	Nov 05 09:00 AM
Yale Catriona	Chief Development Officer	Nov 01 '24	Option Exercise	21.10	15,485	326,734	89,643	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Oct 30 '24	Option Exercise	21.10	4,515	95,266	78,673	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Nov 01 '24	Sale	32.62	15,485	505,105	74,158	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Oct 30 '24	Sale	32.53	4,515	146,855	74,158	Nov 01 08:59 PM
CATRIONA YALE	Officer	Nov 01 '24	Proposed Sale	30.83	29,074	896,351		Nov 01 04:46 PM
Cheng Andrew	President and CEO	Oct 18 '24	Option Exercise	21.10	63,539	1,340,673	668,956	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 16 '24	Option Exercise	21.10	24,992	527,331	630,409	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 17 '24	Option Exercise	21.10	3,103	65,473	608,520	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 18 '24	Sale	31.53	63,539	2,003,328	605,417	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 16 '24	Sale	31.14	24,992	778,151	605,417	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 17 '24	Sale	31.12	3,103	96,559	605,417	Oct 18 08:57 PM
Young Jonathan	Chief Operating Officer	Oct 14 '24	Option Exercise	21.09	40,000	843,600	266,286	Oct 16 08:06 PM
Young Jonathan	Chief Operating Officer	Oct 14 '24	Sale	30.15	40,000	1,206,080	226,286	Oct 16 08:06 PM
Yale Catriona	Chief Development Officer	Oct 15 '24	Option Exercise	0.61	14,825	9,117	90,119	Oct 16 08:06 PM
Yale Catriona	Chief Development Officer	Oct 14 '24	Option Exercise	0.61	5,000	3,075	80,294	Oct 16 08:06 PM
Yale Catriona	Chief Development Officer	Oct 15 '24	Sale	30.50	14,825	452,232	75,294	Oct 16 08:06 PM
Yale Catriona	Chief Development Officer	Oct 14 '24	Sale	30.03	6,136	184,258	74,158	Oct 16 08:06 PM
Andrew Cheng	President, CEO and Director	Oct 16 '24	Proposed Sale	29.82	225,000	6,709,500		Oct 16 04:50 PM
CATRIONA YALE	Officer	Oct 15 '24	Proposed Sale	30.01	32,960	989,130		Oct 15 04:38 PM
CATRIONA YALE	Officer	Oct 14 '24	Proposed Sale	29.63	6,136	181,810		Oct 15 08:04 AM
Young Jonathan	Chief Operating Officer	Oct 01 '24	Sale	28.18	10,000	281,770	226,286	Oct 03 08:09 PM
Jonathan Young	Officer	Oct 01 '24	Proposed Sale	28.51	110,716	3,156,513		Oct 01 04:03 PM
Yale Catriona	Chief Development Officer	Sep 20 '24	Option Exercise	0.61	5,500	3,382	80,794	Sep 23 06:00 PM
Yale Catriona	Chief Development Officer	Sep 20 '24	Sale	27.65	5,500	152,086	75,294	Sep 23 06:00 PM
Yale Catriona	Chief Development Officer	Sep 18 '24	Option Exercise	0.61	3,871	2,381	79,165	Sep 18 09:19 PM
Yale Catriona	Chief Development Officer	Sep 16 '24	Option Exercise	0.61	2,485	1,528	77,779	Sep 18 09:19 PM
Yale Catriona	Chief Development Officer	Sep 17 '24	Option Exercise	0.61	2,037	1,253	77,331	Sep 18 09:19 PM
Yale Catriona	Chief Development Officer	Sep 18 '24	Sale	27.56	3,871	106,685	75,294	Sep 18 09:19 PM
Yale Catriona	Chief Development Officer	Sep 16 '24	Sale	27.52	2,485	68,375	75,294	Sep 18 09:19 PM
Yale Catriona	Chief Development Officer	Sep 17 '24	Sale	27.55	2,037	56,115	75,294	Sep 18 09:19 PM
CATRIONA YALE	Officer	Sep 16 '24	Proposed Sale	27.34	13,893	379,835		Sep 16 04:34 PM
Young Jonathan	Chief Operating Officer	Sep 10 '24	Sale	26.18	568	14,870	236,286	Sep 13 05:16 PM
Yale Catriona	Chief Development Officer	Sep 10 '24	Sale	26.18	637	16,677	75,294	Sep 13 05:14 PM
White William Richard	Chief Financial Officer	Sep 10 '24	Sale	26.18	639	16,729	41,152	Sep 13 05:13 PM
Rolph Timothy	Chief Scientific Officer	Sep 10 '24	Sale	26.18	537	14,059	180,705	Sep 13 05:11 PM
Cheng Andrew	President and CEO	Sep 10 '24	Sale	26.18	1,738	45,501	605,417	Sep 13 05:10 PM
Young Jonathan	Chief Operating Officer	Sep 03 '24	Sale	26.72	5,000	133,588	236,854	Sep 05 04:08 PM
Yale Catriona	Chief Development Officer	Sep 03 '24	Option Exercise	0.61	949	584	76,880	Sep 05 04:05 PM
Yale Catriona	Chief Development Officer	Sep 03 '24	Sale	27.61	949	26,206	75,931	Sep 05 04:05 PM
White William Richard	Chief Financial Officer	Aug 26 '24	Option Exercise	14.57	75,159	1,095,329	74,462	Aug 29 04:30 PM
White William Richard	Chief Financial Officer	Aug 27 '24	Option Exercise	21.09	23,175	488,761	64,966	Aug 29 04:30 PM
White William Richard	Chief Financial Officer	Aug 26 '24	Sale	27.21	75,159	2,045,152	41,791	Aug 29 04:30 PM
White William Richard	Chief Financial Officer	Aug 27 '24	Sale	26.41	23,175	612,098	41,791	Aug 29 04:30 PM
Yale Catriona	Chief Development Officer	Aug 23 '24	Option Exercise	0.61	8,851	5,443	84,782	Aug 28 11:11 AM
Yale Catriona	Chief Development Officer	Aug 26 '24	Option Exercise	0.61	5,200	3,198	81,131	Aug 28 11:11 AM
Yale Catriona	Chief Development Officer	Aug 23 '24	Sale	27.53	8,851	243,641	75,931	Aug 28 11:11 AM
Yale Catriona	Chief Development Officer	Aug 26 '24	Sale	27.51	5,200	143,073	75,931	Aug 28 11:11 AM
White William Richard	Officer	Aug 26 '24	Proposed Sale	27.46	98,334	2,700,252		Aug 26 04:32 PM
CATRIONA YALE	Officer	Aug 23 '24	Proposed Sale	26.11	15,000	391,650		Aug 23 04:27 PM
Cheng Andrew	President and CEO	Aug 16 '24	Option Exercise	0.61	24,538	15,091	607,155	Aug 20 11:45 AM
Young Jonathan	Chief Operating Officer	Aug 01 '24	Sale	26.75	5,000	133,756	241,854	Aug 02 09:32 PM
White William Richard	Chief Financial Officer	Jul 24 '24	Option Exercise	7.01	139,083	974,833	180,874	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 25 '24	Option Exercise	7.01	22,272	156,104	64,063	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 23 '24	Option Exercise	7.01	500	3,504	42,291	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 24 '24	Sale	26.98	139,083	3,753,041	41,791	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 25 '24	Sale	27.61	22,272	614,820	41,791	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 23 '24	Sale	28.01	500	14,005	41,791	Jul 25 05:54 PM
White William Richard	Chief Financial Officer	Jul 16 '24	Option Exercise	7.01	29,803	208,889	76,602	Jul 18 09:41 PM
White William Richard	Chief Financial Officer	Jul 16 '24	Sale	28.04	34,811	976,274	41,791	Jul 18 09:41 PM
Young Jonathan	Chief Operating Officer	Jul 01 '24	Sale	23.40	5,000	117,020	246,854	Jul 02 06:55 PM
Young Jonathan	Chief Operating Officer	Jun 11 '24	Sale	22.64	2,516	56,965	250,790	Jun 13 06:13 PM
Yale Catriona	Chief Development Officer	Jun 11 '24	Sale	22.64	2,825	63,961	74,867	Jun 13 06:11 PM
White William Richard	Chief Financial Officer	Jun 11 '24	Sale	22.64	2,831	64,094	46,799	Jun 13 06:09 PM
Rolph Timothy	Chief Scientific Officer	Jun 11 '24	Sale	22.64	2,380	53,886	180,178	Jun 13 06:06 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 11 '24	Sale	22.64	569	12,883	18,562	Jun 13 06:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience